Therefore, alternative strategies to improve CV outcome are necessary in patients with combined AS and T2DM, in whom the risk of adverse CV events is elevated by 4- to sixfold in asymptomatic severe AS [1], renin-angiotensin antagonists are frequently underused, while surgical or transcatheter aortic valve implantation are limited to subjects with recognized indications to these procedures. This evidence concerns the gene REN and aortic stenosis.